ArticleJournal of experimental pharmacology2021
Silibinin: A New Opportunity for the Treatment of Brain Metastasis from Lung Cancer.
Article in Journal of experimental pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 6 citations in OpenAlex.
- Natural polyphenols as novel interventions for aging and age-related diseases: Exploring efficacy, mechanisms of action and implications for future research.Chinese herbal medicines · 2025Review
- Potential of ex vivo organotypic slice cultures in neuro-oncology.Neuro-oncology · 2025Review
- Review
- Milk Thistle (Current medicinal chemistry · 2025Review
- Exploring Novel Frontiers: Leveraging STAT3 Signaling for Advanced Cancer Therapeutics.Cancers · 2024Review
- Novel Strategies Enhancing Bioavailability and Therapeutical Potential of Silibinin for Treatment of Liver Disorders.Drug design, development and therapy · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite multimodal treatment, the prognosis of brain metastases (BM) remains limited, with a survival of only a few months. In this report, silibinin (or silybin), a natural polyphenolic flavonoid isolated from seed extracts of the herb milk thistle, is discussed as a potential therapeutic option for the treatment of BM. This molecule has an anticancer effect, blocking the migratory and invasive properties of neoplastic cells. This mechanism is focused on controlling the signal transducer and activator of transcription 3 (STAT3)-mediated pathway. STAT3 plays a major role in the growth of tumors and leads to metastasis, including BM. The promising but preliminary clinical results achieved by silibinin on lung cancer BM suggest new opportunities for combined treatment with radiotherapy and/or temozolomide, not just to limit severe neurological symptoms but also to control clinical progression of the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.